Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

By J. Stangier, K. Rathgen, H. Stähle, D. Mazur. Clinical Pharmacokinetics, 2010

753 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery

View Paper: https://www.semanticscholar.org/paper/ccf55e2140fdd29cb609f0f2630d7ff539455936

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Alejandro Rabinstein
2. R. Redberg
3. Nancy R. Cook
4. P. Ridker

In Surgery

1. Alejandro Rabinstein
2. R. Redberg
3. Nancy R. Cook
4. P. Ridker
5. M. Cooper
6. J. Forbes

Citations in the corpus

• Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, background): “A mild (CrCl 50–80 mL/min) to moderate (CrCl 30–49 mL/min) renal insufficiency increases the half-life up to 18 hours and 28 hours in severe renal insufficiency (CrCl 15–29 mL/min).(170,172,173)”
• Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, neutral): “The FDA also approved a reduced dose of dabigatran (75 mg twice daily) for CKD 4 patients based on pharmacokinetic and pharmacodynamic studies.(153)”
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Hemodialysis Due to its low-protein binding (35 %) and high rate of renal excretion, dabigatran can be removed by hemodialysis [197].”